What prices did Mayukh Sukhatme receive for his ROIV share sales?

The reported prices are weighted averages. He sold at $37.17 on August 19 (range $36.80–$37.42), $37.30 on August 20 (range $37.20–$37.51), and $36.48 on August 21 (range $36.25–$37.16). Exact trade-by-trade prices are available upon request to the company or SEC staff.

Roivant president sells 335K shares after option exercise

Q: What insider transactions did ROIV executive Mayukh Sukhatme report on this Form 4?

Mayukh Sukhatme reported exercising stock options for 335,174 Common Shares at $3.85 per share and selling an equal number of 335,174 Common Shares in open-market transactions on August 19–21, 2026, at weighted average prices around $37 per share.

Q: How many Roivant Sciences (ROIV) shares did Mayukh Sukhatme sell and on which dates?

He sold a total of 335,174 Common Shares of Roivant Sciences Ltd.: 172,899 shares on August 19, 2026, 17,519 shares on August 20, 2026, and 144,756 shares on August 21, 2026, all reported as open-market or private sales.

Q: What were the key terms of the stock options exercised by the ROIV executive?

The options were described as an award of stock options to purchase Common Shares that is fully vested, with an exercise price of $3.85 per share and an expiration date of April 19, 2032. In total, options for 335,174 shares were exercised.

Q: Were Mayukh Sukhatme’s Form 4 transactions in ROIV under a Rule 10b5-1 trading plan?

The Form 4’s Rule 10b5-1 checkbox is not marked as affirming that the reported transactions were made pursuant to a Rule 10b5-1 trading plan, and the footnotes do not state that a trading plan applied.

Roivant Sciences Ltd. (ROIV) reported that President & CIO Mayukh Sukhatme exercised stock options and sold the resulting common shares over three days.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) reported that President & CIO Mayukh Sukhatme exercised stock options and sold the resulting common shares over three days. He exercised options covering 335,174 Common Shares at an exercise price of $3.85 per share, fully vested per the award footnote, and received an equal number of Common Shares. On August 19, 20 and 21, 2026, he sold 172,899, 17,519 and 144,756 Common Shares, respectively, at weighted average prices of $37.17, $37.30 and $36.48 per share in multiple transactions within the stated price ranges.

Insider Trade Summary

Exercise and Sale: 335,174 shares ($11.07M approx. pre-tax spread)

Exercise and Sale 9 txns

Insider Sukhatme Mayukh

Role President & CIO

Sold 335,174 shs ($12.36M)

Approx. gross sale proceeds $12.36M

Approx. exercise cost $1.29M

Approx. pre-tax spread $11.07M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^F4	144,756	$0.00	$0.00
Exercise	Common Shares	144,756	$3.85	$557K
Sale	Common Shares ^F3	144,756	$36.48	$5.28M
Exercise	Stock Option (Right to Buy) ^F4	17,519	$0.00	$0.00
Exercise	Common Shares	17,519	$3.85	$67K
Sale	Common Shares ^F2	17,519	$37.30	$653K
Exercise	Stock Option (Right to Buy) ^F4	172,899	$0.00	$0.00
Exercise	Common Shares	172,899	$3.85	$666K
Sale	Common Shares ^F1	172,899	$37.17	$6.43M

Holdings After Transaction: Stock Option (Right to Buy) — 13,224,363 contracts (Direct); Common Shares — 18,630,739 shares (Direct)

Footnotes (4)

F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.80 to $37.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.20 to $37.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $37.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F4. Award of stock options to purchase Common Shares that is fully vested.

Key Figures

Options exercised: 335,174 shares Shares sold: 335,174 shares Option exercise price: $3.85 per share +4 more

7 metrics

Options exercised 335,174 shares Total Common Shares underlying Stock Options (Right to Buy) exercised on August 19–21, 2026

Shares sold 335,174 shares Total Common Shares sold in open-market or private transactions on August 19–21, 2026

Option exercise price $3.85 per share Conversion or exercise price for Stock Options (Right to Buy) expiring April 19, 2032

Weighted average sale price 2026-08-19 $37.17 per share Common Shares sold in multiple transactions at prices ranging from $36.80 to $37.42

Weighted average sale price 2026-08-20 $37.30 per share Common Shares sold in multiple transactions at prices ranging from $37.20 to $37.51

Weighted average sale price 2026-08-21 $36.48 per share Common Shares sold in multiple transactions at prices ranging from $36.25 to $37.16

Option expiration date April 19, 2032 Expiration date for the Stock Option (Right to Buy) awards exercised

Key Terms

Stock Option (Right to Buy), weighted average price, Exercise or conversion of derivative security, fully vested

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" with underlying Common Shares"

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

fully vested financial

"Award of stock options to purchase Common Shares that is fully vested."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ROIV executive Mayukh Sukhatme report on this Form 4?

Mayukh Sukhatme reported exercising stock options for 335,174 Common Shares at $3.85 per share and selling an equal number of 335,174 Common Shares in open-market transactions on August 19–21, 2026, at weighted average prices around $37 per share.

How many Roivant Sciences (ROIV) shares did Mayukh Sukhatme sell and on which dates?

He sold a total of 335,174 Common Shares of Roivant Sciences Ltd.: 172,899 shares on August 19, 2026, 17,519 shares on August 20, 2026, and 144,756 shares on August 21, 2026, all reported as open-market or private sales.

What were the key terms of the stock options exercised by the ROIV executive?

The options were described as an award of stock options to purchase Common Shares that is fully vested, with an exercise price of $3.85 per share and an expiration date of April 19, 2032. In total, options for 335,174 shares were exercised.

Were Mayukh Sukhatme’s Form 4 transactions in ROIV under a Rule 10b5-1 trading plan?

The Form 4’s Rule 10b5-1 checkbox is not marked as affirming that the reported transactions were made pursuant to a Rule 10b5-1 trading plan, and the footnotes do not state that a trading plan applied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/21/2026 - 09:00 PM Accepted by SEC EDGAR 08/21/2026 - 09:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sukhatme Mayukh

(Last)

(First)

(Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON

SW1H 0DB

(City)

(State)

(Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CIO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	08/19/2026		M		172,899	A	$3.85	18,803,638	D
Common Shares	08/19/2026		S		172,899	D	$37.17⁽¹⁾	18,630,739	D
Common Shares	08/20/2026		M		17,519	A	$3.85	18,648,258	D
Common Shares	08/20/2026		S		17,519	D	$37.3⁽²⁾	18,630,739	D
Common Shares	08/21/2026		M		144,756	A	$3.85	18,775,495	D
Common Shares	08/21/2026		S		144,756	D	$36.48⁽³⁾	18,630,739	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$3.85	08/19/2026		M			172,899	⁽⁴⁾	04/19/2032	Common Shares	172,899	$0	13,386,638	D
Stock Option (Right to Buy)	$3.85	08/20/2026		M			17,519	⁽⁴⁾	04/19/2032	Common Shares	17,519	$0	13,369,119	D
Stock Option (Right to Buy)	$3.85	08/21/2026		M			144,756	⁽⁴⁾	04/19/2032	Common Shares	144,756	$0	13,224,363	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.80 to $37.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.20 to $37.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $37.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

4. Award of stock options to purchase Common Shares that is fully vested.

	By: /s/ Sam Kaplan, as Attorney-in-Fact for Mayukh Sukhatme	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR